<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="367117">
  <stage>Registered</stage>
  <submitdate>25/09/2014</submitdate>
  <approvaldate>23/10/2014</approvaldate>
  <actrnumber>ACTRN12614001124628</actrnumber>
  <trial_identification>
    <studytitle>Dexmedetomidine Versus Nefopam for management of post spinal anesthesia shivering:A randomized double-blind controlled study</studytitle>
    <scientifictitle>Dexmedetomidine Versus Nefopam for management of post spinal anesthesia shivering</scientifictitle>
    <utrn>U1111-1161-9559</utrn>
    <trialacronym>D  vs. N. In psash.</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Post spinal anesthesia shivering</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>dexmedetomidine in a dose of 0.5Ug/Kg intravenous(i.v.) or Nefopam in a dose of 0.15mg/Kg I.v. In the respective groups.each drug was diluted into 5 ml by isotonic saline and given by slow I.v.( one minute) at the onset of shivering.either of the two drugs was given according to the group in the postoperative spinal anesthesia period to patients who develop grade III or IV shivering . When shivering recures additional dose of either of the two drugs according to the group can be given as the same previous dose and recorded.</interventions>
    <comparator>Dexmedetomidine group is being compared to Nefopam group.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time of stoppage of postspinal anesthesia shivering  after treatment with either dexmedetomidine or Nefopam.</outcome>
      <timepoint>We record shivering  every minute  after  I. V. Injection of either dexmedetomidine or Nefopam for the first five minutes of the injections  and record time of its stoppage after treatment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of effective postspinal analgesia after treatment with either dexmedetomidine or Nefopam. It is calculated from intrathecal bupivacaine injection to patient first request for rescue analgesic guided by visual analogue scale .  Adverse effects are not outcome of the study.</outcome>
      <timepoint>Duration of effective postspinal analgesia from intrathecal bupivacaine administration to first rescue analgesic request.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>ASA I and II patients scheduled for elective lower abdominal,lower limb , orthopedic  and plastic surgeries under spinal anesthesia</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Known hypersensitivity to dexmedetomidine  or  Nefopam,cardiopulmonary,renal or hepatic diseases,patients with a contra indication to spinal anesthesia  e.g coagulation disorders,patients with failed or partial spinal block  or those who do not agree to participate in the study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>Numerical data will be presented as mean+/- SD and categorical data as proportions. The unpaired t- test will be used for comparison of the means of all variables between the two groups.p. value of less than 0.05  will be considered statistically significant. We hypothesized that  a detectable difference between the means  of time taken for cessation of post spinal shivering after treatment with either dexmedetomidine or Nefopam = 180 seconds. If we estimated a S.D. For this prospective power analysis as 20%and an alpha value of 0.05,the power of the study would be 90%.Sample size calculated to be 45.7 patients per group .To increase the power we enrolled 50 patients per group.
</statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>False</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>1/11/2014</anticipatedstartdate>
    <actualstartdate>1/11/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate>1/03/2015</actualenddate>
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state>Qena</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>South valley university</primarysponsorname>
    <primarysponsoraddress>South valley university-Qena-postal code 85823</primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>South valley  university( SVU).</fundingname>
      <fundingaddress>South valley university-Qena-postal code 85823</fundingaddress>
      <fundingcountry>Egypt</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress>Nil</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>We will compare dexmedetomidine and Nefopam  for  treatment of postspinal anesthesia shivering  regarding time of  stoppage of shivering,effective postspinal anesthesia time .</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Qena faculty of medicine ethics committee</ethicname>
      <ethicaddress>Qena- south valley university- postal code 85823</ethicaddress>
      <ethicapprovaldate>10/09/2014</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>1/09/2014</ethicsubmitdate>
      <ethiccountry>Egypt</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Hatem saber Mohamed</name>
      <address>Qena faculty of medicine- south valley university- postal code 85823-Qena.</address>
      <phone>+201005257062</phone>
      <fax />
      <email>dr.hatem_saber@hotmail.com</email>
      <country>Egypt</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Hatem saber Mohamed</name>
      <address>Qena faculty of medicine- south valley university- postal code 85823-Qena.</address>
      <phone>+201005257062</phone>
      <fax />
      <email>dr.hatem_saber@hotmail.com</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Hatem saber Mohamed</name>
      <address>Qena faculty of medicine- south valley university- postal code 85823-Qena.</address>
      <phone>+201005257062</phone>
      <fax />
      <email>dr.hatem_saber@hotmail.com</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>